Windtree surges after cardiac shock drug succeeds in study

Windtree Therapeutics

20/04/2022 13:17

** Windtree Therapeutics Inc's shares  WINT.O  up 41% at
$1.41 premarket; set for their biggest jump in over two years,
if gains hold 
    ** Co's experimental drug for cardiogenic shock, istaroxime,
met the main goal of a mid-stage study  urn:newsml:reuters.com:*:nGNX91XwWs
    ** Co says the drug was significantly better at rapidly
raising systolic blood pressure in the study versus a placebo 
    ** Raising systolic blood pressure is a key clinical
objective in treating patients in cardiac shock
    ** Cardiogenic shock is a serious condition that occurs when
the heart is failing significantly and cannot pump enough blood
and oxygen to the brain, kidneys and other vital organs
    ** Stock down ~37% YTD

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15))